Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Chemo in Operable Urothelial Cancer (SAKK 06/17)
NCT03406650Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- May 2018
- Primary completion
- Feb 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 2
01
Overview
A Phase 2 trial of durvalumab in urothelial carcinoma (UC), sponsored by Swiss Group for Clinical Cancer Research. Started May 2018; status: completed.
02
Drugs
durvalumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03406650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03406650.